Tom Hallam, Palisade Bio CEO
September 16, 2022 11:20 AM EDTUpdated 01:10 PM
People
R&D

Pal­isade Bio is the lat­est to re­struc­ture, hun­ker­ing down on its lead pro­gram

Tyler Patchen

News Reporter

Like so many oth­er biotechs in the bear mar­ket, Pal­isade Bio is look­ing to play the re­org game and lay off parts of its staff …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times